Sorrento Therapeutics, Inc. Business Finance Contracts & Agreements
122 Contracts & Agreements
- Assignment Agreements (2 contracts)
- Contribution Agreements (4)
- Credit Agreements (4)
- Equity Distribution Agreements (1)
- Escrow Agreements (2)
- Exchange Agreements (2)
- Indenture Agreements (2)
- Investment Agreements (2)
- Loan Agreements (19)
- Note Agreements (7)
- Purchase Agreements (11)
- Registration Rights Agreements (12)
- Release Agreements (1)
- Share Agreements (2)
- Stock Agreements (29)
- Subordination Agreement (1)
- Term Sheets (6)
- Underwriting Agreements (4)
- Warrant Agreements (11)
- Asset Purchase Agreement, dated October 30, 2023, between Yuhan Corporation and Sorrento Therapeutics, Inc (Filed With SEC on November 3, 2023)
- Stock Purchase Agreement, dated September 29, 2023, between Dr. Robert J. Hariri, M.D., Ph. D., and Sorrento Therapeutics, Inc (Filed With SEC on October 5, 2023)
- Assignment, Assumption and Release Agreement, dated September 21, 2023, between Scilex Holding Company, Oramed Pharmaceuticals, Inc., Sorrento Therapeutics, Inc. and Scintilla... (Filed With SEC on September 26, 2023)
- Stock Purchase Agreement, dated September 21, 2023, between Scilex Holding Company and Sorrento Therapeutics, Inc (Filed With SEC on September 26, 2023)
- Second Amendment to Stock Purchase Agreement, dated August 21, 2023, between Sorrento Therapeutics, Inc. amd Oramed Pharmaceuticals Inc (Filed With SEC on August 28, 2023)
- Senior Secured, Super-Priority Debtor-In-Possession Loan and Security Agreement, dated March 30, 2023, by and among Sorrento Therapeutics, Inc., Scintilla Pharmaceuticals, Inc.,... (Filed With SEC on August 10, 2023)
- Amendment Agreement to Stock Purchase Agreement, Dated August 9, 2023, between Sorrento Therapeutics, Inc. amd Oramed Pharmaceutircals Inc (Filed With SEC on August 10, 2023)
- Stock Purchase Agreement, Dated August 7, 2023 between Sorrento Therapeutics, Inc. and Oramed Pharmaceuticals Inc (Filed With SEC on August 10, 2023)
- Intercreditor and Subordination Agreement, dated as of July 5, 2023, by and among JMB Capital Partners Lending, LLC and Scilex Holding Company (Filed With SEC on July 10, 2023)
- Debtor-in-Possession Term Loan Facility Summary of Terms and Conditions, dated as of July 5, 2023, between Sorrento Therapeutics, Inc., Scintilla Pharmaceuticals, Inc. and Scilex... (Filed With SEC on July 10, 2023)
- Senior Secured, Super-Priority Debtor-In-Possession Loan and Security Agreement, dated March 30, 2023, by and among Sorrento Therapeutics, Inc., Scintilla Pharmaceuticals, Inc.,... (Filed With SEC on March 31, 2023)
- Bridge Loan Agreement, dated as of September 30, 2022, by and between Sorrento Therapeutics, Inc. and B. Riley Commercial Capital, LLC (Filed With SEC on November 8, 2022)
- Contribution and Satisfaction of Indebtedness Agreement, dated as of September 12, 2022, by and among Sorrento Therapeutics, Inc., Scilex Holding Company and Scilex... (Filed With SEC on September 14, 2022)
- Consent Under and Amendment No. 4 to Indenture, dated June 3, 2022, by and among Sorrento Therapeutics, Inc., Scilex Pharmaceuticals Inc., U.S. Bank Trust Company, National... (Filed With SEC on June 3, 2022)
- Form of Amended and Restated Registration Rights Agreement (Filed With SEC on March 18, 2022)
- Loan Agreement, dated January 6, 2018, by and between Zhejiang ACEA Pharmaceutical Co., Ltd. and ACEA Bio (Hangzhou) Co., Ltd. (translated into English from its original text in... (Filed With SEC on June 4, 2021)
- Sorrento Therapeutics, Inc. Stock Appreciation Rights Award Agreement (Filed With SEC on May 5, 2021)
- Sorrento Therapeutics, Inc. 2021 Cash-Settled Stock Appreciation Rights Plan (Filed With SEC on May 5, 2021)
- Amendment to Binding Term Sheet, dated as of April 20, 2021, by and between Sorrento Therapeutics, Inc. and ANP Technologies, Inc (Filed With SEC on May 5, 2021)
- Binding Term Sheet, dated as of February 24, 2021, by and between Sorrento Therapeutics, Inc. and ANP Technologies, Inc (Filed With SEC on May 5, 2021)
- Binding Term Sheet, dated as of October 14, 2020, by and between Sorrento Therapeutics, Inc. and ACEA Therapeutics, Inc (Filed With SEC on February 19, 2021)
- Consent Under and Amendment No. 3 to Indenture and Letter of Credit, dated December 14, 2020, by and among Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc., U.S. Bank... (Filed With SEC on December 15, 2020)
- Sorrento Therapeutics, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on October 20, 2020)
- First Amendment to Exchange and Registration Rights Agreement, dated September 28, 2020, by and between Sorrento Therapeutics, Inc. and Fortis Advisors LLC in its capacity as the... (Filed With SEC on October 2, 2020)
- Omnibus Amendment No. 2 to Indenture and Letter of Credit, dated as of March 30, 2020, by and among Scilex Pharmaceuticals, Inc., Sorrento Therapeutics, Inc., U.S. Bank National... (Filed With SEC on May 11, 2020)
- Common Stock Purchase Agreement, dated as of April 27, 2020, by and between Sorrento Therapeutics, Inc. and Arnaki Ltd (Filed With SEC on April 27, 2020)
- Common Stock Purchase Agreement, dated as of February 10, 2020, by and between Sorrento Therapeutics, Inc. and Aspire Capital Fund, LLC (Filed With SEC on February 11, 2020)
- Registration Rights Agreement, dated as of February 10, 2020, by and between Sorrento Therapeutics, Inc. and Aspire Capital Fund, LLC (Filed With SEC on February 11, 2020)
- Amendment No. 2 to the Registration Rights Agreement, dated as of December 6, 2019, by and among Sorrento Therapeutics, Inc. and the persons party thereto (Filed With SEC on December 9, 2019)
- Form of Warrant, dated December 6, 2019, issued by Sorrento Therapeutics, Inc (Filed With SEC on December 9, 2019)
- Note Conversion Agreement, dated as of November 8, 2019, by and among Sorrento Therapeutics, Inc. and the holders of convertible notes issued by Sorrento Therapeutics, Inc. as is... (Filed With SEC on November 12, 2019)
- Form of Securities Purchase Agreement, dated October 7, 2019, by and between the Company and the purchasers party thereto (Filed With SEC on October 8, 2019)
- Omnibus Amendment No. 1 to Indenture and Letter of Credit, dated as of October 1, 2019, by and among Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc., U.S. Bank National... (Filed With SEC on October 1, 2019)
- Equity Distribution Agreement, dated as of October 1, 2019, by and between Sorrento Therapeutics, Inc. and JMP Securities LLC (Filed With SEC on October 1, 2019)
- Form of Series C Warrant (Filed With SEC on June 28, 2019)
- Form of Series B Warrant (Filed With SEC on June 28, 2019)
- Form of Series A Warrant (Filed With SEC on June 28, 2019)
- Underwriting Agreement, dated as of June 28, 2019, by and between Sorrento Therapeutics, Inc. and JMP Securities LLC, as representative of the underwriters named therein (Filed With SEC on June 28, 2019)
- Amendment No. 1 to Term Loan Agreement, dated as of May 3, 2019, by and among Sorrento Therapeutics, Inc., certain subsidiaries of Sorrento Therapeutics, Inc., as guarantors,... (Filed With SEC on May 3, 2019)
- Amendment No. 1 to the Registration Rights Agreement, dated as of May 3, 2019, by and among Sorrento Therapeutics, Inc. and the persons party thereto (Filed With SEC on May 3, 2019)
